tradingkey.logo

Medpace Holdings Inc

MEDP
查看详细走势图
561.650USD
-7.200-1.27%
收盘 12/31, 16:00美东报价延迟15分钟
15.78B总市值
38.30市盈率 TTM

Medpace Holdings Inc

561.650
-7.200-1.27%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.27%

5天

-1.79%

1月

-4.48%

6月

+74.93%

今年开始到现在

0.00%

1年

+69.05%

查看详细走势图

TradingKey Medpace Holdings Inc股票评分

单位: USD 更新时间: 2025-12-31

操作建议

Medpace Holdings Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名41/403位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价536.35。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Medpace Holdings Inc评分

相关信息

行业排名
41 / 403
全市场排名
130 / 4560
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 13 位分析师
持有
评级
536.351
目标均价
-2.33%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Medpace Holdings Inc亮点

亮点风险
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
业绩高增长
公司营业收入稳步增长,连续3年增长44.46%
利润高增长
公司净利润处于行业前列,最新年度总收入2.11B美元
估值高估
公司最新PE估值38.30,处于3年历史高位
机构减仓
最新机构持股26.75M股,环比减少5.75%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值936.00
活跃度降低
近期活跃度降低,过去20天平均换手率0.05

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Medpace Holdings Inc简介

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
公司代码MEDP
公司Medpace Holdings Inc
CEOTroendle (August J)
网址https://investor.medpace.com/

常见问题

Medpace Holdings Inc(MEDP)的当前股价是多少?

Medpace Holdings Inc(MEDP)的当前股价是 561.650。

Medpace Holdings Inc的股票代码是什么?

Medpace Holdings Inc的股票代码是MEDP。

Medpace Holdings Inc股票的52周最高点是多少?

Medpace Holdings Inc股票的52周最高点是626.255。

Medpace Holdings Inc股票的52周最低点是多少?

Medpace Holdings Inc股票的52周最低点是250.050。

Medpace Holdings Inc的市值是多少?

Medpace Holdings Inc的市值是15.78B。

Medpace Holdings Inc的净利润是多少?

Medpace Holdings Inc的净利润为404.34M。

现在Medpace Holdings Inc(MEDP)的股票是买入、持有还是卖出?

根据分析师评级,Medpace Holdings Inc(MEDP)的总体评级为持有,目标价格为536.351。

Medpace Holdings Inc(MEDP)股票的每股收益(EPS TTM)是多少

Medpace Holdings Inc(MEDP)股票的每股收益(EPS TTM)是14.665。
KeyAI